Photosensitisers for the photodynamic therapy of cancer and other diseases

Bibliography

• DOUGHERTY TJ, GOMER CJ, HENDERSON BW etal.: Photodynamic therapy. j Natl. Cancer Inst. (1998) 32:889–905.
   Google Scholar
• HENDERSON BW, DOUGHERTY TJ: How does photodynamic therapy work? Photochem. PhotabiaL (1992) 55:145–157.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the principles and practice of PDT.
   Google Scholar
• KATO H: Photodynamic therapy for lung cancer - a review of 19 years' experience. Photochem. PhotabiaL B. (1998) 42:96–99.
   PubMed Web of Science ®Google Scholar
• GUILLEMIN F, FEINTRENIE X, LIGNON D: Photodynamic therapy of bronchial cancers. Rev Prieumologie (1992) 48:111–114.
   Google Scholar
• PUOLAKKAINEN E SCHRODER T: Photodynamic therapy of gastrointestinal tumors: a review. Dig. Dis. (1992) 10:53–60.
   PubMed Web of Science ®Google Scholar
• NOSKE DP, WOLBERS JG, STEREENBORG HJ: Photodynamic therapy of malignant glioma. A review of literature. OM. Neural. Neurosurg. (1991) 93:293–307.
   PubMed Web of Science ®Google Scholar
• MOESTA KT, SCHLAG P, DOUGLAS JR. HO, MANG TS: Evaluating the role of photodynamic therapy in the management of pancreatic cancer. Lasers Surg. Med. (1995) 16:84–92.
   Google Scholar
• SHARMAN WM, ALLEN CM, VAN LIER JE: Photodynamic therapeutics: basic principles and clinical applications. Drug Discovery Today (1999) 4:507–517.
   PubMed Web of Science ®Google Scholar
• BELLNIER DA, DOUGHERTY TJ: A preliminary pharmacokinetic study of intravenous photofrin in patients. Laser Med. Surg. (1996) 14:311–314.
   Google Scholar
• DOUGHERTY TJ, MARCUS SL: Photodynamic therapy. Eur. I Cancer (1992) 28A:1734–1742.
   PubMed Web of Science ®Google Scholar
• STERNBERG ED, DOLPHIN D, BRÜCKNER C: Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron (1998) 54:4151–4202.
   Web of Science ®Google Scholar
• PASS HI: Photodynamic therapy in oncology: mechanisms and clinical use. Natl. Cancer Inst. (1993) 85:443–456.
   Google Scholar
• ROSENTHALL DI, GLATSTEIN E: Clinical applications of photodynamic therapy. Ann. Medicine (1994) 26:405–409.
   PubMed Web of Science ®Google Scholar
• HENDERSON BW, DOUGHERTY TJ, (Eds): Photodynamic Therapy: Basic Principles and Clinical Aspects. Marcel Dekker, New York, USA (1992):1–459.
   Google Scholar
• PENNING LC, DUBBELMAN TM: Fundamentals of photodynamic therapy: cellular and biochemical aspects. Anti-Cancer Drugs (1994) 5:139–146.
   PubMed Web of Science ®Google Scholar
• WAN S, PARRISH JA, ANDERSON RR, MADDEN M: Transmittance of nonionizing radiation in human tissue. Photochem. PhotabiaL (1981) 34:679–684.
   PubMed Web of Science ®Google Scholar
• SVAASAND LO: Optical dosimetry for direct and interstitial photodynamic therapy of malignant tumors. In: Porphyrin Localization and Treatment of Tumors. Doirona DR, Gomer CJ, Liss AR (Eds.) New York, USA (1984):91–114.
   Google Scholar
• JACQUES SL, PRAHL SA: Modeling optical and thermal distribution in tissue during laser irradiation. Laser Surg. Med. (1987) 6:494–503.
   PubMed Web of Science ®Google Scholar
• STABLES GI, ASH DV: Photodynamic therapy. Cancer Treat. Rev (1995) 21:311–323.
   PubMed Web of Science ®Google Scholar
• RIS HB, ALTERMATT HJ, STEWART CM etal.: Photodynamic therapy with m-tetrahydroxyphenyl chlorin in vivo: optimization of the therapeutic index. Inter. Cancer (1993) 55:245–249.
   Google Scholar
• BONNETT R, WHITE RD, WINFIELD UJ, BERENBAUM MC: Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumor photosensitizers. Biochem. (1989) 261:277–280.
   Google Scholar
• MORGAN AR, GARBO GM, KECK RW, SELMAN SH: New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. Cancer Res. (1988) 48:194–198.
   PubMed Web of Science ®Google Scholar
• STERNBERG ED, DOLPHIN D, BRÜCKNER C: Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron (1998) 54:4151–4202.
   Web of Science ®Google Scholar
• •A compilation of all of the various porphyrin, chlorin, and related structures that have been examined as PDT photosensitisers.
   Google Scholar
• POTTER WR, HENDERSON BW, BELLNIER DA et al.: Parabolic quantitative structure-activity relationships and photodynamic therapy: Application of a three-component model with clearance to the in vivo quantitative structure-activity relationships of a congeneric series of pyropheophorbide derivatives used as photosensitizers for photodynamic therapy. Photochem. Photobiol (1999) 70:781–788.
   PubMed Web of Science ®Google Scholar
• ROVERS JP, SAARNAK AE, DE JODE M, STERENBORG HJ, TERPSTRA OT: Biodistribution and bioactivity of tetra-pegylated meta-tetra(hydroxyphenyfi chlorin compared to native meta-tetra(hydroxyphenyfi chlorin in a rat liver tumor model. Photochem. Photobiol (2000) 71:211–217.
   PubMed Web of Science ®Google Scholar
• HORNUNG R, FEHR MK, MONTI-FRAYNE J et al: Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model. Photochem. Photobiol (1999) 70:624–629.
   PubMed Web of Science ®Google Scholar
• HORNUNG R, FEHR MK, MONTI-FRAYNE J, TROMBERG BJ, BERNS MW, TADIR Y: Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC. Br. j Cancer (1999) 81:631–637.
   PubMed Web of Science ®Google Scholar
• SESSLER JL, HEMMI G, MODY TD, MURAI T, BURRELL A, YOUNG SW: Texaphyrins: synthesis and applications. Acc. Chem. Res. (1994) 27:43–50.
   Web of Science ®Google Scholar
• •A review of the synthesis and chemical properties of the core-expanded porphyrins.
   Google Scholar
• SESSLER JL, MILLER RA: Texaphyrins - new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol (2000) 59:733–739.
   PubMed Web of Science ®Google Scholar
• •A review of the effects of different metal-atoms in the expanded porphyrin core on the biological proeprties of these molecules.
   Google Scholar
• BERNHARD EJ, MITCHELL JB, DEEN D, CARDELL M, ROSENTHALL DI, BROWN JM: Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. (2000) 60:86–91.
   PubMed Web of Science ®Google Scholar
• ALLISON RMD, MANG TS: Low-dose photofrin-induced PDT offers excellent clinical response with minimal morbidity in chest wall recurrence of breast cancer. Proc. SPIE-Int. Soc. Opt. Eng. (2000) 3909(Optical Methods for Tumor Treatment and Detection: Mechanism and Teechniques in Photodynamic Therapy IX):20–24.
   Google Scholar
• SCHMIDT S: Photodynamic therapy inbreast cancer patients: application of SnET2 for skin metastases. Photomed. Cyriecol Reprod. (2000) 316–321.
   Google Scholar
• COLUSSI VC, FEYES DK, MULVIHILL JW et al: Phthalocyanine 4 (Pc4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. Photobiol (1999) 69:236–241.
   PubMed Web of Science ®Google Scholar
• MARGARONE E GREGOIRE M-J, SCASNART V, ALI H, VANLIER JE: Structure-photodynamic relationships of a series of 4-substituted zinc phthalocyanines. Photochem. Photobiol (1996) 63:217–223.
   PubMed Web of Science ®Google Scholar
• BEN-HUR E, MALIK Z, DUBBELMAN TMAR, MARGARONE P, ALI H, VAN LIER JE: Phthalocyanine-induced photohemolysis: structure-activity relationship and the effect of fluoride. Photochem. Photobiol (1993) 58:351–355.
   PubMed Web of Science ®Google Scholar
• PENG Q, MOAN J, MA LW NESLAND JM: Uptake, localization, and photodynamic effect of mesa-tetra(hydroxypheny9porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res. (1995) 55:2620–2626.
   PubMed Web of Science ®Google Scholar
• PENG Q, MOAN J, NESLAND JM: Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol (1996) 20:109–129.
   PubMed Web of Science ®Google Scholar
• HILF R, MURANT RS, NARAYANAN U, GIBSON SL: Relationship of mitochondrial function and cellular adenosine triphosphate levels to hematoporphyrin derivative-induced photosensitization in R3230AC mammary tumors. Cancer Res. (1986) 46:211–217.
   PubMed Web of Science ®Google Scholar
• GIBSON SL, MURANT RS, CHAZEN MD, KELLY ME, HILF R: In vitro photosensitization of tumor cell enzymes by Photofrin II administered in vivo. Br Cancer (1989) 59:47–53.
   Google Scholar
• SHARKEY SM, WILSON BC, MOOREHEAD R, SINGH G: Mitochondrial alterations in photodynamic therapy-resistant cells. Cancer Res. (1993) 53:4994–4999.
   PubMed Web of Science ®Google Scholar
• VERMA A, FACCHINA SL, HIRSCH DJ etal.: Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target. Mal Med. (1998) 4:40–445.
   Google Scholar
• NOODT BB, RODAL GH, WAINWRIGHT M et al: Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells. _kir Cancer (1998) 75:941–948.
   Web of Science ®Google Scholar
• •An excellent description of photosensitiser role in apoptosis with PDT.
   Google Scholar
• KESSEL D, LUO Y, DENG Y, CHANG CK: The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem. Photobiol (1997) 65:422–426.
   PubMed Web of Science ®Google Scholar
• STILTS CE, NELEN MI, HILMEY DG et al.: Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. j Med. Chem. (2000) 43:2403–2410.
   PubMed Web of Science ®Google Scholar
• ULMAN A, MANASSEN J, FROLOW F, RABINOVICH D: Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: II. Tetrapheny1-21-selena-23-thiaporphyrin and tetrapheny1-21,23-diselenaporphyrin. Tetrahedron Lett. (1978) 167–170.
   Google Scholar
• ULMAN A, MANASSEN J, FROLOW F, RABINOVICH D: Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: III. Tetrapheny1-21-tellura-23-thiaporphyrin: an internally-bridged porphyrin. Tetrahedron Lett. (1978) 1885–1886.
   Google Scholar
• ULMAN A, MANASSEN J: Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: Part 4. Symmetrically and unsymmetrically substituted tetrapheny1-21,23-dithiaporphyrins. j Chem. Soc. Perkin Trans. 1(1979) 4:1066-1069.
   Google Scholar
• LATOS-GRAZYNSKI L, LISOWSKI J, OLMSTEAD MM, BALCH AL: Five-coordinate complexes of 21-thiaporphyrin. The preparation, spectra and structures of nickel(II), and copper(II) complexes. Iriorg. Chem. (1989) 28:1183–1188.
   Google Scholar
• LATOS-GRAZYNSKI L, LISOWSKI J, CHMIELEWSKI PJ, OLMSTEAD MM, BALCH AL: Synthesis of 5,20-dipheny1-10,15-bis(p-toly1)-21-selenaporphyrin (SeDPDTPH). Inorg. Chem. (1996) 35:566–573.
   Google Scholar
• ZIOLKOWSKI P, MILACH J, SYMONOWICZ K, CHMIELEWSKI P, LATOS-GRAZYNSKI L, MAECINKOWSKA E: 5,20-Bis(4-sulphopheny1)-10,15-bis(2-methoxy-4-sulfopheny1)-21-thiaporphyrin as a new potent sensitizer in photodynamic therapy. Tumori (1996) 81:364–369.
   Google Scholar
• MARCINKOWSKA E, ZIOLKOWSKI P, PACHOLSKA E, LATOS-GRAZYNSKI, CHMIELEWSKI P, RADZIKOWSKI CZ: The new sensitizing agents for photodynamic therapy: 21-selenaporphyrin and 21-thiaporphyrin. Anticancer Res. (1997) 17:3313–3320.
   PubMed Web of Science ®Google Scholar
• FISHER M, VOGTLE F: Dendrimers: from design to application - a progress report. Angew. Chem. Int. Ed. Engl. (1999) 38:884–905.
   PubMed Web of Science ®Google Scholar
• Vogtle F: Dendrimers. Top. Curr. Chem. Springer, Berlin, Germany (1998):1–197.
   Google Scholar
• •An excellent review of the properties and applications of dendrimer molecules.
   Google Scholar
• MOHR H, LAMBRECHT B, SELZ A: Photodynamic virus inactivation of blood components. Immurrol. Invest. (1995) 24:73–85.
   PubMed Web of Science ®Google Scholar
• MOHR H, LAMBRECHT B, SCHMITT H: Photo-inactivation of viruses in therapeutical plasma. Dev. Biol. Stand. (1993) 81:177–183.
   PubMedGoogle Scholar
• WAGNER SJ, ROBINETTE D, STORY J,CHEN XY, SHUMAKER J, BENADE L: Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion (1994) 34:521–526.
   PubMed Web of Science ®Google Scholar
• WAINWRIGHT M: Non porphyrin photosensitizers in biomedicine. Chem. .Sc. Rev (1996) 32:351–359.
   Google Scholar
• •A complement to reference 23 for non-porphyrin sensitisers including cationic dyes.
   Google Scholar
• CINCOTTA L, FOLEY JW, CINCOTTA AH: Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells. Cancer Res. (1993) 53:2571–2580.
   PubMed Web of Science ®Google Scholar
• LIN CW, SHULOK JR, KIRLEY SD et al.: Photodynamic destruction of lysosomes mediated by nile blue photosensitizers. Photochem. Photobiol. (1993) 58:81–91.
   PubMed Web of Science ®Google Scholar
• LIN CW, SHULOK JR, KIRLEY SD, CINCOTTA L, FOLEY JW: Lysosomal localization and mechanism of uptake of nile blue photosensitizers in tumor cells. Cancer Res. (1991) 51:2710–2719.
   PubMed Web of Science ®Google Scholar
• CINCOTTA L, FOLEY JW, MACEACHEM T, LAMPROS E, CINCOTTA AH: Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res. (1994) 54:1249–1258.
   PubMed Web of Science ®Google Scholar
• JOHNSON LV, WALSH ML, BOCKUS BJ, CHEN LB: Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. j Cell Biol. (1981) 88:526–535.
   PubMed Web of Science ®Google Scholar
• MITCHELL P: Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Glynn Research Ltd., Bodmin. (1966):1–205.
   Google Scholar
• SUMMERHAYES IC, LAMPIDIS TJ, BERNAL SD et al.: Unusual retention of rhodamine 123 by mitochondria in smooth muscle and carcinoma cells. Proc. Natl. Acad. Sci. USA (1982) 79:5292–5296.
   PubMed Web of Science ®Google Scholar
• DAVIS S, WEISS MJ, WONG JR, LAMPIDIS TJ, CHEN LB: Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by breast adenocarcinoma-derived MCF-7 cells. j Biol. Chem. (1985) 260:13844–13850.
   PubMed Web of Science ®Google Scholar
• BERNAL SD, LAMPIDIS TJ, MCISAAC RM, CHEN LB: Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science (1986) 221:169–172.
   Google Scholar
• KESSEL D, WOODBURN K: Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitizing agent. Br .j Cancer (1995) 71:306–310.
   PubMed Web of Science ®Google Scholar
• HARAPANHALLI RS, ROY AM, ADELSTEIN SJ, KASSIS Al: [1251/1271/ 131I1 lodorhodamine: synthesis, cellular localization, and biodistribution in athymic mice bearing human tumor xenografts and comparison with [99nTc1hexakis(2-methoxyisobutylisonitrile). j Med. Chem. (1998) 41:2111–2117.
   PubMed Web of Science ®Google Scholar
• DETTY MR, MERKEL PB, HILF R, GIBSON SL, POWERS SK: Chalcogenapyrylium dyes as photochemotherapeutic agents. 2. Tumor uptake, mitochondrial targeting, and singlet-oxygen-induced inhibition of cytochrome c oxidase. j Med. Chem. (1990) 33:1108–1116.
   Google Scholar
• •A quantitative account of the effects of different heteroatoms on chemical and photophysical properties.
   Google Scholar
• DETTY MR, MERKEL PB: Chalcogenapyrylium dyes as potential photochemotherapeutic agents. Solution studies of heavy atom effects on triplet yields, quantum efficiencies of singlet oxygen generation, rates of reaction with singlet oxygen, and emission quantum yields. J Am. Chem. Soc. (1990) 112:3845–3855.
   Google Scholar
• POWERS SK, WALSTAD DL, BROWN JT, DETY MR, WATKIN PJ: Chalcogenapyrylium dyes as sensitizers for photodynamic therapy. I Neurooncol. (1989) 7:179–183.
   PubMedGoogle Scholar
• BELLNIER DA, YOUNG DN, DETTY MR, CAMACHO S, OSEROFF AR: pH-dependent chalcogenopyrylium dyes as potential sensitizers for PDT. Selective retention in tumor by exploiting pH differences between tumor and normal tissue. Photochem. Photobiol. (1999) 70:630–636.
   Google Scholar
• LEONARD KA, NELEN MI, ANDERSON LT, GIBSON SL, HILF R, DETTY MR: 2,4,6-Triarylchalcogeno-pyrylium dyes related in structure to the antitumor agent AA-1 as in vitro sensitizers for the photodynamic therapy of cancer. Med. Chem. (1999) 42:3942–3952.
   Web of Science ®Google Scholar
• •Defines the necessity of two nitrogen atoms in cationic photosensitisers.
   Google Scholar
• LEONARD KA, NELEN MI, SIMARD TP et al.: Synthesis and evaluation of chalcogenopyrylium dyes as potential sensitizers for the photodynamic therapy of cancer. j Med. Chem. (1999) 42:3953–3964.
   PubMed Web of Science ®Google Scholar
• OSEROFF AR, ARA G, OHUOHA D et al.: Strategies for selective cancer photochemotherapy: antibody-targeted and selective carcinoma cell photolysis. Photochem. Photobiol. (1987) 46:83–96.
   PubMed Web of Science ®Google Scholar
• OSEROFF AR, OHUOHA D, ARA G, MCAULIFFE D, FOLEY J, CINCOTTA L: Intramitochondrial ayes allow selective in vitro photolysis of carcinoma. Proc. Nati Acad. Sci. USA (1986) 83:9729–9733.
   PubMed Web of Science ®Google Scholar
• ARA G, APRILLE JR, MALIS CD etal.:Mechanisms of mitochondrial photosensitization by the cationic dye, NN'-bis(2-ethy1-1,3-dioxylene)-Itryptocyanine (EDKC): preferential inactivation of complex I in the electron transport chain. Cancer Res. (1987) 47:6580–6585.
   Google Scholar
• LEE C, WU SS, CHEN LB: Photosensitization by 3,3'-dicyclohexyl-oxacarbocyanine iodide: specific disruption of microtubules and inactivation of organelle motility. Cancer Res. (1995) 55:2063–2069.
   PubMed Web of Science ®Google Scholar
• MODICA-NAPOLITANO JS, BRUNELLI BT, KOYA K, CHEN LB: Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077. Cancer Res. (1998) 58:71–75.
   PubMed Web of Science ®Google Scholar
• MODICA-NAPOLITANO JS, JOYAL JL,ARA G, OSEROFF AR, APRILLE JR: Mitochondria' toxicity of cationic photosensitizers for photochemotherapy. Cancer Res. (1990) 50:7876–7881.
   PubMed Web of Science ®Google Scholar
• MORGAN J, WHITAKER JE, OSEROFF AR: GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue BO. Photochem. Photobiol (1998) 67:155–164.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI M, KOYA K, UKAI T etal.: Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity. j Med. Chem. (1997) 40:3151–3160.
   Google Scholar
• SUN X, WONG JR, SONG K, HU J, GARLID KD, CHEN LB: AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res. (1994) 54:1465–1471.
   PubMed Web of Science ®Google Scholar
• LEONARD KA, HALL JP, NELEN MI et al.: A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization. j Med. Chem. (2000) 43:4488–4498.
   PubMed Web of Science ®Google Scholar